Ula Jurkunas is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 203 publications with 6,044 citations (h-index 45); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
243 Charles St
Mass Eye And Ear Infirmary
Boston, MA 021143002
Telephone
617-573-6897Registry record last updated 7 Jun 2013.
Clinical trials
- Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
Sponsor: Massachusetts Eye and Ear Infirmary
- Assessment of Corneal Endothelial Function Following Hypoxic Stress
Sponsor: Massachusetts Eye and Ear Infirmary
- Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
Sponsor: Massachusetts Eye and Ear Infirmary
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kowa Pharmaceuticals America, Inc.Program year20251 payment
- Ziemer USAProgram year20251 payment
- Kowa Research Institute, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
59.4%Corticosteroid49.7%Prednisolone Acetate66%Fluorometholone34%Part D≥93 patientsCorticosteroids, plain7.4%Difluprednate39%Lotemax30%Loteprednol Etabonate30%Part D<11 patients+ 1 more class in this area
Anti-infectives
24.6%Macrolide11.7%Erythromycin100%Part D≥22 patientsFluoroquinolone Antibacterial9.2%Moxifloxacin100%Part D≥31 patients+ 1 more class in this area
Dermatology
5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor5%Acyclovir100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Role of Oxidative Stress in Pathogenesis of Fuchs Endothelial Corneal Dystrophy
Schepens Eye Research Institute
FY2026$607,779R01EY020581 - Role of Oxidative Stress in Pathogenesis of Fuchs Endothelial Corneal Dystrophy
Schepens Eye Research Institute
FY2025$602,106R01EY020581 - Role of Oxidative Stress in Pathogenesis of Fuchs Endothelial Corneal Dystrophy
Schepens Eye Research Institute
FY2024$632,258R01EY020581
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cell cycle re-entry and arrest in G2/M phase induces senescence and fibrosis in Fuchs Endothelial Corneal Dystrophy
Free Radical Biology and Medicine
2021 - Fuchs endothelial corneal dystrophy: The vicious cycle of Fuchs pathogenesis
Progress in Retinal and Eye Research
2020 - Corneal endothelial dysfunction: Evolving understanding and treatment options
Progress in Retinal and Eye Research
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Dean Eliott, MD
Massachusetts Eye and Ear Infirmary
Leo Kim, MD
Massachusetts Eye and Ear Infirmary
Daniel Liebman, MD
Massachusetts Eye and Ear Infirmary
Reza Dana, MD, MSE, MPH
Massachusetts Eye and Ear Infirmary
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”